β-Galactose Dehydrogenase Inhibitors

Chemical inhibitors of β-Galactose Dehydrogenase encompass a variety of compounds that interfere with the enzyme's ability to catalyze the oxidation of β-galactose. Phenylboronic acid is known for its affinity to diols, enabling it to bind to carbohydrates such as β-galactose. This binding prevents the proper interaction of β-galactose with β-Galactose Dehydrogenase, inhibiting the enzyme's function. Similarly, 2-Deoxy-D-galactose acts as a competitive inhibitor due to its structural resemblance to β-galactose, occupying the active site of the enzyme and thus blocking the actual substrate from associating with β-Galactose Dehydrogenase. Compounds like Fidarestat, Sorbinil, Tolrestat, Epalrestat, Ponalrestat, Zopolrestat, and Alrestatin, which are primarily aldose reductase inhibitors, have a mode of action that involves binding to the active site of their target enzymes. By this mechanism, these inhibitors can occupy the active site of β-Galactose Dehydrogenase, preventing the enzyme from interacting with β-galactose.

On the other hand, DAB, known for its inhibitory effects on aldehyde dehydrogenase, can bind to β-Galactose Dehydrogenase, resulting in the obstruction of the enzyme's catalytic action. Collectively, these inhibitors engage with β-Galactose Dehydrogenase in a manner that disrupts its natural catalytic cycle, effectively diminishing the enzyme's ability to process its substrate, β-galactose.